Personalised treatment of patients with immune thrombotic thrombocytopenic purpura
The duration of therapy with caplacizumab, rituximab and glucocorticoids in patients with iTTP should be determined by the achievement of target ADAMTS13 activity.
Authors
- Е. Н. Паровичникова (ORCID: https://orcid.org/0000-0001-6177-3566)
- З. Т. Фидарова (ORCID: https://orcid.org/0000-0003-0934-6094)
- S. Yu. Mamleeva (ORCID: https://orcid.org/0000-0003-1492-1735)
- Е. Е. Клебанова (ORCID: https://orcid.org/0000-0002-8141-9422)
- G. М. Galstyan (ORCID: https://orcid.org/0000-0001-8818-8949)
- Mikhail Drokov (ORCID: https://orcid.org/0000-0001-9431-8316)
- П. П. Авдонин (ORCID: https://orcid.org/0000-0002-7701-772X)
Institutions
- Koltzov Institute of Developmental Biology (RU)
Publication Details
- Journal
- Terapevticheskii arkhiv
- Published
- 2025-08-28
- DOI
- https://doi.org/10.26442/00403660.2025.08.203326
- Primary Topic
- Complement system in diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00